Neuroinflammatory Disease

A Boston-area biotech company has received $24 million in Series A funding to develop neurorestorative and remyelinating therapies for a broad range of neurological conditions.

Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.

Treatment with TNF inhibitors are associated with an increased — albeit still low — risk for neuroinflammatory disease in patients with ankylosing spondylitis and psoriatic arthritis, but not rheumatoid arthritis, according to data published in the Annals of the Rheumatic Diseases.